About Stromelysin-2
Stromelysin-2 (MMP10) is a protein
from Homo sapiens identified by UniProt accession
P09238, 476 residues long.
MolForge cross-references it against 0 known binders and
399 disease associations.
Target properties
| Protein name | Stromelysin-2 |
|---|
| UniProt accession | P09238 |
|---|
| Gene | MMP10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 476 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (399)
Diseases linked to this target (Open Targets).
- matrix metalloproteinase 10 measurement · score 0.48
- blood protein measurement · score 0.47
- lung adenocarcinoma · score 0.24
- breast adenocarcinoma · score 0.22
- glioblastoma multiforme · score 0.21
- PHF-tau measurement · score 0.17
- cutaneous melanoma · score 0.15
- essential tremor · score 0.11
- neoplasm · score 0.11
- breast cancer · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P09238-F1 | alphafold | PREDICTED | 86.13 | — |
Amino-acid sequence (476 residues)
MMHLAFLVLL CLPVCSAYPL SGAAKEEDSN KDLAQQYLEK YYNLEKDVKQ FRRKDSNLIV KKIQGMQKFL GLEVTGKLDT DTLEVMRKPR CGVPDVGHFS SFPGMPKWRK THLTYRIVNY TPDLPRDAVD SAIEKALKVW EEVTPLTFSR LYEGEADIMI SFAVKEHGDF YSFDGPGHSL AHAYPPGPGL YGDIHFDDDE KWTEDASGTN LFLVAAHELG HSLGLFHSAN TEALMYPLYN SFTELAQFRL SQDDVNGIQS LYGPPPASTE EPLVPTKSVP SGSEMPAKCD PALSFDAIST LRGEYLFFKD RYFWRRSHWN PEPEFHLISA FWPSLPSYLD AAYEVNSRDT VFIFKGNEFW AIRGNEVQAG YPRGIHTLGF PPTIRKIDAA VSDKEKKKTY FFAADKYWRF DENSQSMEQG FPRLIADDFP GVEPKVDAVL QAFGFFYFFS GSSQFEFDPN ARMVTHILKS NSWLHC
Explore Stromelysin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets